Stocks · News reference
ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA®
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
ImmunityBio has completed the database lock for Cohort A of its QUILT-2.005 registrational trial, which evaluates ANKTIVA in combination with BCG for BCG-naïve non-muscle invasive bladder cancer.
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.